Oxford stops COVID-19 vaccine study in kids, expecting more data on blood clot issues
LONDON (UK) – The University of Oxford said on Tuesday it had stopped a small UK trial testing of the COVID-19 vaccine it developed with AstraZeneca Plc in children and teenagers, as it awaits more data on rare blood clotting issues in adults who have gotten themselves a jab.
The trial disruption is the latest blow to the vaccine, seen as a milestone in the fight against the pandemic, after several countries limited its use in the wake of reports of medical issues following inoculations.
There were no safety concerns in the pediatric trial, as per Oxford University. It added that it would seek guidance from the UK drugs watchdog before setting out on any further vaccinations.
The European Medicines Agency (EMA) is currently evaluating reports of an extremely rare brain blood clot called cerebral venous sinus thrombosis (CVST) after the AstraZeneca shots. It is expected to make an announcement of its findings on Wednesday or Thursday.
A senior EMA official has said there is a clear association between the vaccine and CVST, despite having the direct cause of the clots as unknown.
There has been arguments with governments across Europe with regard to production, supplies, possible side effects.